Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. (17th November 2020)

• Record Type: Journal Article
• Authors: Reddy, Krishna P; Denkinger, Claudia M; Broger, Tobias; McCann, Nicole C; Gupta-Wright, Ankur; Kerkhoff, Andrew D; Pei, Pamela P; Shebl, Fatma M; Fielding, Katherine L; Nicol, Mark P; Horsburgh, C Robert; Meintjes, Graeme; Freedberg, Kenneth A; Wood, Robin; Walensky, Rochelle P
• Is Part Of: Clinical infectious diseases. Volume 73:Number 7(2021)
• Page Start: e2077
• Page End: e2085
• Publication Date: 2020-11-17
• Subjects: tuberculosis -- HIV -- diagnosis -- lipoarabinomannan -- cost-effectiveness; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1698
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: A novel urine lipoarabinomannan assay (FujiLAM) has higher sensitivity and higher cost than the first-generation AlereLAM assay. We evaluated the cost-effectiveness of FujiLAM for tuberculosis testing among hospitalized people with human immunodeficiency virus (HIV), irrespective of symptoms. Methods: We used a microsimulation model to project clinical and economic outcomes of 3 testing strategies: (1) sputum Xpert MTB/RIF ( Xpert ), (2) sputum Xpert plus urine AlereLAM ( Xpert+AlereLAM ), (3) sputum Xpert plus urine FujiLAM ( Xpert+FujiLAM ). The modeled cohort matched that of a 2-country clinical trial. We applied diagnostic yields from a retrospective study (yields for Xpert / Xpert+AlereLAM / Xpert+FujiLAM among those with CD4 <200 cells/µL: 33%/62%/70%; among those with CD4 ≥200 cells/µL: 33%/35%/47%). Costs of Xpert/AlereLAM/FujiLAM were US$15/3/6 (South Africa) and $25/3/6 (Malawi). Xpert+FujiLAM was considered cost-effective if its incremental cost-effectiveness ratio (US$/year-of-life saved) was <$940 (South Africa) and <$750 (Malawi). We varied key parameters in sensitivity analysis and performed a budget impact analysis of implementing FujiLAM countrywide. Results: Compared with Xpert+AlereLAM, Xpert+FujiLAM increased life expectancy by 0.2 years for those tested in South Africa and Malawi. Xpert+FujiLAM was cost-effective in both countries. Xpert+FujiLAM for all patients remained cost-effective compared with sequential testing and CD4-stratified testing strategies. FujiLAM use added 3.5% (South Africa) and 4.7% (Malawi) to 5-year healthcare costs of tested patients, primarily reflecting ongoing HIV treatment costs among survivors. Conclusions: FujiLAM with Xpert for tuberculosis testing in hospitalized people with HIV is likely to increase life expectancy and be cost-effective at the currently anticipated price in South Africa and Malawi. Additional studies should evaluate FujiLAM in clinical practice settings. Abstract : Testing hospitalized patients with human immunodeficiency virus (HIV) in South Africa and Malawi for tuberculosis by the novel FujiLAM urine assay is likely to increase life expectancy and be cost-effective. These results can inform decisions about implementing FujiLAM testing.